valine has been researched along with Hyperpotassemia in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Käser, L; Kolyvanos Naumann, U; Vetter, W | 1 |
| Oparil, S; Patel, S; Satlin, A; Yarows, SA; Zhang, J | 1 |
| Chrysant, SG; Dattani, D; Hoppe, UC; Hsu, H; Murray, AV; Patel, S; Zhang, J | 1 |
| Cannon, SC; George, AL; Green, DS; Hayward, LJ | 1 |
| Armstrong, PW; Borer, J; Fleming, T; Lipicky, R | 1 |
5 other study(ies) available for valine and Hyperpotassemia
| Article | Year |
|---|---|
[Hyperkalemia. Main symptoms: muscle weakness, cardiac arrhythmias].
Topics: Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiography; Heart Failure; Humans; Hyperkalemia; Hypertension; Male; Middle Aged; Muscle Weakness; Spironolactone; Tetrazoles; Valine; Valsartan | 2004 |
Dual inhibition of the renin system by aliskiren and valsartan.
Topics: Amides; Antihypertensive Agents; Drug Therapy, Combination; Fumarates; Humans; Hyperkalemia; Hypertension; Renin; Tetrazoles; Valine; Valsartan | 2007 |
Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
Topics: Aged; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Fumarates; Humans; Hydrochlorothiazide; Hyperkalemia; Hypertension; Male; Middle Aged; Renin; Renin-Angiotensin System; Risk Factors; Tetrazoles; Time Factors; Valine; Valsartan | 2008 |
A proposed mutation, Val781Ile, associated with hyperkalemic periodic paralysis and cardiac dysrhythmia is a benign polymorphism.
Topics: Adult; Arrhythmias, Cardiac; Cell Line; Child; Humans; Hyperkalemia; Isoleucine; Male; Muscle, Skeletal; Paralyses, Familial Periodic; Point Mutation; Polymorphism, Genetic; Protein Structure, Secondary; Recombinant Proteins; Sodium Channels; Transfection; Valine | 1997 |
Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.
Topics: Adrenergic beta-Antagonists; Advisory Committees; Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Black People; Canada; Cardiovascular Agents; Drug Approval; Heart Failure; Humans; Hyperkalemia; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Renal Insufficiency; Spironolactone; Survival Rate; Tetrazoles; United States; United States Food and Drug Administration; Valine; Valsartan | 2001 |